Vaxcyte, Inc.
PCVX US92243G1085
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
Annual Performance 1
2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
-12% | 82% | 33% | 30% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Eydelman Mikhail VP |
72.37 USD |
112 Sold |
8,105 USD |
05/03/2025 | 05/03/2025 |
Eydelman Mikhail VP |
70.39 USD |
2,621 Sold |
184,487 USD |
05/03/2025 | 05/03/2025 |
Eydelman Mikhail VP |
71.07 USD |
2,267 Sold |
161,107 USD |
05/03/2025 | 05/03/2025 |
Wassil Jim COO |
73.84 USD |
2,085 Sold |
153,950 USD |
27/02/2025 | 03/03/2025 |
Wassil Jim COO |
73.07 USD |
5,915 Sold |
432,215 USD |
27/02/2025 | 03/03/2025 |
Guggenhime Andrew PR |
83.64 USD |
6,182 Sold |
517,056 USD |
18/02/2025 | 18/02/2025 |
Guggenhime Andrew PR |
84.58 USD |
1,818 Sold |
153,766 USD |
18/02/2025 | 18/02/2025 |
Eydelman Mikhail VP |
89.09 USD |
635 Sold |
56,571 USD |
05/02/2025 | 05/02/2025 |
Eydelman Mikhail VP |
91.05 USD |
1,784 Sold |
162,437 USD |
05/02/2025 | 05/02/2025 |
Eydelman Mikhail VP |
89.95 USD |
1,755 Sold |
157,860 USD |
05/02/2025 | 05/02/2025 |